InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
In the Media
InMed Pharmaceuticals leading the development of cannabinol CBN therapeutics – Executive Interview with CEO Eric A. Adams
Share this post
Latest Media News
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to
InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat